Tendon mechanisms and translational research · Lab and clinical study · 2023
What do shockwaves do inside a tendon?
This review gathered lab and animal research on how shockwaves affect tendons. At some doses, cells, blood vessels and tendon tissue showed changes that may support repair. Higher doses sometimes harmed cells or tissue. It did not look at pain or function in patients.
Explores how shockwave works- studies reviewed
- 23
- kinds of animals: rats, rabbits, horses, ponies, dogs
- 5
- cell-culture studies
- 6
Good to know: Based on 23 lab and animal studies up to December 2021; responses varied by species, tendon and dose.
Poenaru D, Sandulescu MI, Cinteza D Biomedical Reports, 2023 · Read the paper ↗
The treatment
- Review exposure scope
- Focused and radial ESWT protocols varied by experimental model, tendon, energy-flux density, pulse count and schedule; no single patient protocol can be extracted.
- Comparator
- Study-specific contralateral-limb, untreated or laboratory comparison conditions; no pooled clinical comparator.
Who took part
No patients were treated: lab studies of tendon cells and tissue, including two studies of human tendon tissue, plus animal studies.
Side effects
In some lab and animal studies, higher doses reduced cell survival and caused tissue damage or inflammation. The review did not look at side effects in patients.
All the numbers and the full appraisal
What the full paper reports.
The evidence spans animal tendon models, human tendon tissue studies and in-vitro cultures. The authors describe in-vivo work in rats, rabbits, horses, ponies and dogs, two human tissue studies, and six cell-culture papers. This is a heterogeneous evidence map, not a patient cohort.
Study-specific histology, cell viability, biochemical, vascular and biomechanical assessments1 reported outcome
Tendon biological and structural responses to ESWT
Study-specific histology, cell viability, biochemical, vascular and biomechanical assessments Qualitative synthesis
The review describes varied, dose-related responses across models. Some exposures accompanied cellular, vascular, matrix and biomechanical changes interpreted as potentially reparative; higher exposures also produced reduced viability or structural disruption in some models. The review does not quantify clinical pain or functional benefit.
Analysis details and source
Narrative synthesis of 23 records; animal and in-vitro results are not patient outcomes. Studies with quantitative pain/function assessments were excluded.
How treatment was delivered
Focused and radial ESWT protocols varied by experimental model, tendon, energy-flux density, pulse count and schedule; no single patient protocol can be extracted.
Study-specific contralateral-limb, untreated or laboratory comparison conditions; no pooled clinical comparator.
Some experimental models showed dose-related cell-viability reduction and tissue changes including collagen disorganization, necrosis or inflammatory reactions. The review does not estimate clinical adverse events.
The evidence combines species, tendon sites, tissue states, exposure settings and experimental methods. In-vitro and animal findings cannot be assumed to predict patient outcomes. Search was limited to PubMed and Cochrane, to full texts available at the authors' institution, and to studies available through December 2021; quantitative pain/function studies were excluded.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- The evidence combines species, tendon sites, tissue states, exposure settings and experimental methods. In-vitro and animal findings cannot be assumed to predict patient outcomes. Search was limited to PubMed and Cochrane, to full texts available at the authors' institution, and to studies available through December 2021; quantitative pain/function studies were excluded.
Source-linked critical reading
Systematic mechanistic review with human, animal and laboratory components
Technical source record
Full-text XML read from Introduction through disclosures. Reviewed study selection, Table I, all mechanistic results, discussion, both figure captions and end-matter. Supplementary material was not identified.
This article reviews how shockwaves may affect tendon cells and tissue. Most findings come from laboratory or animal research, and the review excluded studies measuring pain and function. It therefore cannot predict whether treatment will help a particular person or identify a best dose.
Which biological responses to ESWT have been reported in human, animal and cell-culture tendon studies, and how do dose and tissue model shape those responses?
Systematic mechanistic review of 23 full-text records selected from 7,120 titles identified in PubMed and Cochrane searches through December 2021. Quantitative pain and function studies were excluded.
The evidence spans animal tendon models, human tendon tissue studies and in-vitro cultures. The authors describe in-vivo work in rats, rabbits, horses, ponies and dogs, two human tissue studies, and six cell-culture papers. This is a heterogeneous evidence map, not a patient cohort.
The review covers focused and radial ESWT exposures with different energy-flux densities, pulse counts and schedules. Protocols vary by species, tendon, normal versus diseased tissue, and laboratory versus living-tissue model; the review does not establish a transferable clinical regimen.
Many in-vivo experiments used the contralateral limb as control; cell and tissue studies used study-specific untreated or comparison conditions. These are not a single comparator or pooled patient-treatment contrast.
The review synthesizes viability, angiogenesis, cellular activity, extracellular-matrix turnover, inflammatory mediators and biomechanical properties qualitatively. It explicitly excluded quantitative pain and function outcomes.
Across models, the authors describe dose-related biological responses, with potentially regenerative changes at some exposures and reduced cell viability or structural disruption at higher exposures. Responses varied by species and tendon. These mechanistic observations do not estimate clinical benefit.
Structural damage, collagen disorganization, inflammatory reaction and reduced cell viability were reported in some experimental models at higher exposures. The review does not provide a patient-level adverse-event estimate; absence of such an estimate is not evidence of zero clinical harms.
The evidence combines species, tendon sites, tissue states, exposure settings and experimental methods. In-vitro and animal findings cannot be assumed to predict patient outcomes. Search was limited to PubMed and Cochrane, to full texts available at the authors' institution, and to studies available through December 2021; quantitative pain/function studies were excluded.
This review supports biological plausibility and highlights dose- and tissue-specific responses. It cannot tell patients how likely pain relief or functional recovery is, identify an optimal clinical dose, or establish comparative effectiveness.
Clinical studies should prespecify diagnosis-specific protocols and patient-important outcomes, while translational experiments should report species, tendon, tissue state, device parameters, controls and timing in enough detail to test dose-response without treating one model as universal.
Read the original article.
Biological effects of extracorporeal shockwave therapy in tendons: A systematic review.
Poenaru D, Sandulescu MI, Cinteza D. · Biomedical reports · 2023
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →